Cancer Research AACR Membership Advances in Breast Cancer Research
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Li, X.
Right arrow Articles by Marcelli, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Li, X.
Right arrow Articles by Marcelli, M.
[Cancer Research 61, 186-191, January 1, 2001]
© 2001 American Association for Cancer Research

Experimental Therapeutics

Adenovirus-mediated Bax Overexpression for the Induction of Therapeutic Apoptosis in Prostate Cancer1

Xiaoying Li2, Michela Marani2, Jiang Yu, Bicheng Nan, Jack A. Roth, Shunsuke Kagawa, Bingliang Fang, Larry Denner and Marco Marcelli3

Departments of Medicine [X. L., M. Mara., J. Y., B. N., M. Marc.] and Molecular and Cellular Biology [M. Marc.], Baylor College of Medicine and Veterans Affairs Medical Center; Department of Thoracic and Cardiovascular Surgery, M. D. Anderson Cancer Center [J. A. R., S. K., B. F.]; and Department of Molecular and Cellular Biology, Texas Biotechnology Corporation [L. D.], Houston, Texas 77030

Using adenoviral technology, we overexpressed the proapoptotic molecules pro-caspase-3, pro-caspase-7, and Bax to induce therapeutic apoptosis of prostate cancer cell lines growing in vitro and in vivo. Because overexpressed pro-caspase-3 did not undergo autocatalytic activation in any of the five prostate cancer cell lines evaluated, this strategy was unable to engage any component of the apoptotic pathway. Overexpressed pro-caspase-7 was proteolytically cleaved in LNCaP and LnCaP-Bcl-2 cells but not in PC-3, DU-145, or TsuPr(1) cells. Cleavage was associated with engagement of many components of the apoptotic pathway, including DEVDase activity, cleavage of intracellular caspase targets such as the DNA fragmentation factor and the proapoptotic Bid, release of cytochrome c from the mitochondria to the cytoplasm, and terminal deoxynucleotidyl transferase-mediated nick end labeling. No apoptosis was observed in the cells where caspase-7 did not undergo autocatalytic activation. Searching for an approach that would more reliably induce therapeutic apoptosis of prostate cancer cell lines, we used a binary adenoviral system to overexpress the proapoptotic molecule Bax. Bax was dramatically overexpressed and caused apoptosis of every cell line infected by engaging the mitochondrial pathway, including proteolytic cleavage and catalytic activation of the caspases, cleavage of caspase substrates, release of cytochrome c from the mitochondria, and DNA fragmentation. Furthermore, three injections of the Bax overexpression system into PC-3 cell tumors in nude mice in vivo caused a 25% regression in tumor size corresponding to a 90% reduction relative to continued tumor growth in animals that received injections with the control binary system expressing Lac-Z. These experiments show that adenovirus-mediated Bax overexpression is capable of inducing therapeutic programmed cell death in vitro and in vivo by activating the mitochondrial pathway of apoptosis. On the basis of these studies, we conclude that manipulation of Bax expression is an attractive new gene therapy approach for the treatment of prostate cancer.




This article has been cited by other articles:


Home page
 Clin. Cancer Res.Home page
L. Y. Khor, J. Moughan, T. Al-Saleem, E. H. Hammond, V. Venkatesan, S. A. Rosenthal, M. A. Ritter, H. M. Sandler, G. E. Hanks, W. U. Shipley, et al.
Bcl-2 and Bax Expression Predict Prostate Cancer Outcome in Men Treated with Androgen Deprivation and Radiotherapy on Radiation Therapy Oncology Group Protocol 92-02
Clin. Cancer Res., June 15, 2007; 13(12): 3585 - 3590.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
T. Fukazawa, Y. Maeda, M. L. Durbin, T. Nakai, J. Matsuoka, H. Tanaka, Y. Naomoto, and N. Tanaka
Pulmonary adenocarcinoma-targeted gene therapy by a cancer- and tissue-specific promoter system
Mol. Cancer Ther., January 1, 2007; 6(1): 244 - 252.
[Abstract] [Full Text] [PDF]

Home page
 Antimicrob. Agents Chemother.Home page
H. Servais, Y. Jossin, F. Van Bambeke, P. M. Tulkens, and M.-P. Mingeot-Leclercq
Gentamicin Causes Apoptosis at Low Concentrations in Renal LLC-PK1 Cells Subjected to Electroporation.
Antimicrob. Agents Chemother., April 1, 2006; 50(4): 1213 - 1221.
[Abstract] [Full Text] [PDF]

Home page
 Mol. Cell. Biol.Home page
Y. Lin, J. Kokontis, F. Tang, B. Godfrey, S. Liao, A. Lin, Y. Chen, and J. Xiang
Androgen and its receptor promote bax-mediated apoptosis.
Mol. Cell. Biol., March 1, 2006; 26(5): 1908 - 1916.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Ma, V. Lakshmikanthan, R. W. Lewis, and M. V. Kumar
Sensitization of TRAIL-resistant cells by inhibition of heat shock protein 90 with low-dose geldanamycin
Mol. Cancer Ther., January 1, 2006; 5(1): 170 - 178.
[Abstract] [Full Text] [PDF]

Home page
 J. Clin. Endocrinol. Metab.Home page
J. Pan, H. Huang, L. Sun, B. Fang, and S.-C. J. Yeung
Bcl-2-Associated X Protein Is the Main Mediator of Manumycin A-Induced Apoptosis in Anaplastic Thyroid Cancer Cells
J. Clin. Endocrinol. Metab., June 1, 2005; 90(6): 3583 - 3591.
[Abstract] [Full Text] [PDF]

Home page
 GutHome page
Y Tsunemitsu, S Kagawa, N Tokunaga, S Otani, T Umeoka, J A Roth, B Fang, N Tanaka, and T Fujiwara
Molecular therapy for peritoneal dissemination of xenotransplanted human MKN-45 gastric cancer cells with adenovirus mediated Bax gene transfer
Gut, April 1, 2004; 53(4): 554 - 560.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Pathol.Home page
M. Grzmil, P. Thelen, B. Hemmerlein, S. Schweyer, S. Voigt, D. Mury, and P. Burfeind
Bax Inhibitor-1 Is Overexpressed in Prostate Cancer and Its Specific Down-Regulation by RNA Interference Leads to Cell Death in Human Prostate Carcinoma Cells
Am. J. Pathol., August 1, 2003; 163(2): 543 - 552.
[Abstract] [Full Text] [PDF]

Home page
 Nucleic Acids ResHome page
D. Falke, M. Fisher, D. Ye, and R. L. Juliano
Design of artificial transcription factors to selectively regulate the pro-apoptotic bax gene
Nucleic Acids Res., February 1, 2003; 31(3): e10 - e10.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
M. A. Eid, R. W. Lewis, and M. V. Kumar
Mifepristone Pretreatment Overcomes Resistance of Prostate Cancer Cells to Tumor Necrosis Factor {alpha}-related Apoptosis-inducing Ligand (TRAIL)
Mol. Cancer Ther., August 1, 2002; 1(10): 831 - 840.
[Abstract] [Full Text] [PDF]

Home page
 Clin. Cancer Res.Home page
C. G. Ferreira, M. Epping, F. A. E. Kruyt, and G. Giaccone
Apoptosis: Target of Cancer Therapy
Clin. Cancer Res., July 1, 2002; 8(7): 2024 - 2034.
[Abstract] [Full Text] [PDF]

Home page
 J. Biol. Chem.Home page
O. E. Pardo, A. Arcaro, G. Salerno, S. Raguz, J. Downward, and M. J. Seckl
Fibroblast Growth Factor-2 Induces Translational Regulation of Bcl-XL and Bcl-2 via a MEK-dependent Pathway. CORRELATION WITH RESISTANCE TO ETOPOSIDE-INDUCED APOPTOSIS
J. Biol. Chem., March 29, 2002; 277(14): 12040 - 12046.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
W. Lu, J. Lin, and J. Chen
Expression of p14ARF Overcomes Tumor Resistance to p53
Cancer Res., March 1, 2002; 62(5): 1305 - 1310.
[Abstract] [Full Text] [PDF]

Home page
 Molecular Cancer TherapeuticsHome page
Y. Tong, Q. Yang, C. Vater, L.K. Venkatesh, D. Custeau, T. Chittenden, G. Chinnadurai, and H. Gourdeau
The Pro-apoptotic Protein, Bik, Exhibits Potent Antitumor Activity That Is Dependent on Its BH3 Domain
Mol. Cancer Ther., December 1, 2001; 1(2): 95 - 102.
[Abstract] [Full Text] [PDF]

Home page
 JNCI J Natl Cancer InstHome page
F. Andriani, B. Nan, J. Yu, X. Li, N. L. Weigel, M. J. McPhaul, S. Kasper, S. Kagawa, B. Fang, R. J. Matusik, et al.
Use of the Probasin Promoter ARR2PB to Express Bax in Androgen Receptor-Positive Prostate Cancer Cells
J Natl Cancer Inst, September 5, 2001; 93(17): 1314 - 1324.
[Abstract] [Full Text] [PDF]

Home page
 Cancer Res.Home page
X. Xie, X. Zhao, Y. Liu, J. Zhang, R. J. Matusik, K. M. Slawin, and D. M. Spencer
Adenovirus-mediated Tissue-targeted Expression of a Caspase-9-based Artificial Death Switch for the Treatment of Prostate Cancer
Cancer Res., September 1, 2001; 61(18): 6795 - 6804.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2001 by the American Association for Cancer Research.